Navigation Links
Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
Date:8/11/2011

THE WOODLANDS, Texas, Aug. 11, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Wedbush 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011 at 1:15 p.m. Eastern Time in New York City.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com.  An archived version of the webcast will be available for 30 days after the event on the company's website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
2. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
4. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
8. Lexicon to Provide First Quarter 2011 Financial Results
9. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
10. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017 Derek ... Potts Law Firm, was recently appointed Liaison Counsel in ... (JCCP) for all Xarelto cases. In this role, Potts ... parties and will actively assist the Court and Co ... with Milstein Adelman Jackson Fairchild & ...
(Date:1/16/2017)... When synthetic Fentanyl arrived on the streets in 2015, dealers ... free samples, inviting would-be customers to test a newly-created batch. ... The rapidly-growing demand for the ... morphine, has racked up a staggering death toll across ... recorded fentanyl sales reveals that they have sold nearly 400 ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... titled, "Vital Signs Monitoring Devices Market by Type and End ... the global vital signs monitoring devices market size was worth ... million by 2022, growing at a CAGR of 5.8% from ... the leading regional market in global vital signs monitoring devices ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... In 1985, the ... high-level training standards to an international multidisciplinary group of healthcare treatment providers and ... way to further its mission at the grassroots level, iaedp launched MemberSHARE, an ...
(Date:1/16/2017)... ... 16, 2017 , ... NexTec Group has been selected as a member of ... their accomplishments in the field of midmarket financial software. , Members of the VAR ... Selection is not based on revenue and those firms chosen represent a wide range ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... The Gravity ... location in Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing ... Gravity Vaults sixth location, including three in New Jersey and two in New York. ...
(Date:1/14/2017)... ... 14, 2017 , ... AgileMinder develops innovative products and services that bring "Care, ... available on Apple as a fun, free emoji sticker pack for iMessage. Use the ... ten color coded values on The Emoji Scale. , On Apple: "The Emoji ...
Breaking Medicine News(10 mins):